Why Novel Nanoparticle-based Delivery Platforms Hold Key for HIV/AIDS Treatment and Prevention?
Journal Title: HIV/AIDS Research and Treatment – Open Journal - Year 2016, Vol 2, Issue 3
Abstract
The administration of highly active antiretroviral therapy (HAART) to HIV/AIDS patients has greatly reduced their morbidity and mortality. However, HAART regimens have myriad of limitations, which make it difficult to completely eradicate HIV/AIDS from the body. Cells harboring latent HIV reside in restricted areas in the body: cellular and anatomical reservoirs. The residing of HIV in these restricted sanctuaries makes HAART regimens incapable of completely eliminating HIV from the body. In addition, HAART regimens have to be taken for a lifetime making AIDS patients develop resistance to the drugs. When HIV/AIDS patients take HAART regimens overtime, the drugs result in side effects, such as drug toxicities and treatment fatigue. The development of nanotechnology has revolutionized medicine today. Nanotechnology have the potential to mitigate the challenges that doctors and scientists are facing with the current treatment and prevention of HIV/AIDS. In this review, I discuss the challenges of HAART regimens and how the novel nanoparticle-based delivery platforms can be advanced for HIV/AIDS treatment and prevention.
Authors and Affiliations
Michael Ochieng Otieno
Keywords
Related Articles
- EP ID EP555290
- DOI 10.17140/HARTOJ-2-113
- Views 116
- Downloads 0
Homelessness, Mental Illness, Substance Abuse, and HIV: An Insidious Syndemic
Background: This cross-sectional study examined the effects of face-to-face (real) and virtual social support networks on the mental health status of Japanese HIV-positive males. Method: A nationwide online cross-section...
Relationship between Knowledge of Someone Infected With HIV/AIDS and HIV Stigma: A Moderated Mediation Model of HIV Knowledge, Gender and HIV Test Uptake
Introduction: Sub-Saharan Africa has been particularly impacted by the HIV epidemic with an estimated 24.7 million out of 36.9 million people living with HIV/AIDS (PLWH). Nigeria has the second highest number of people l...
Test and Start for People Living With HIV and Who Use Drugs in Low and Middle Income Countries
“Test and Start” implements the World Health Organization (WHO) recommendation of “treat all” by providing anti-retroviral treatment to persons newly diagnosed with HIV infection, at the time of their diagnosis. This HIV...
A Rare Case of BCGiosis With Severe Combined Immunodeficiency
Background: Bacille Calmette-Guerin (BCG), a live attenuated vaccine, is safe and given to all neonates in endemic countries; however may rarely cause disseminated disease, especially in immuno-deficient individuals. Cas...
Engagement of African Americans with Rapid HIV Testing and HIV Care
Introduction/Background: African Americans and Blacks experience the greatest human immunodeficiency virus (HIV) burden of any racial group in the US and globally. A number of challenges contribute to the higher rates of...